Original researchPhase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Cited by (0)
Presented at: Presented at 2019 American Society of Clinical Oncology Annual Meeting, 2 June 2019, Chicago, Illinois.
Contributors: Conceptualisation: GCO, VZ, NRF, EJA, JAC and SJW. Data curation: GCO, VZ, XH, NRF, EJA and SJW. Formal analysis: GCO, VZ, XH, NRF, EJA and SJW. Funding acquisition: GCO and SJW. Investigation: GCO, VZ, XH, NRF, AEWH, AJ, MSB, CLL, GEC, TAD, MWR, JKC, KAB, JAC and SJW. Methodology: GCO, VZ, XH, EJA and SJW. Project administration: GCO, VZ, XH and SJW. Resources: GCO and SJW. Software: NRF, EJA and SJW. Supervision: GCO, VZ, NRF, EJA, AEWH, AJ, MSB, CLL, GEC, TAD, MWR, JKC, KAB, JAC and SJW. Validation: GCO, VZ, XH, NRF, EJA and SJW. Visualisation: GCO. Writing – original draft: GCO, VZ, XH, NRF, EJA, AEWH, AJ, MSB, CLL, GEC, TAD, MWR, JKC, KAB, JAC and SJW. Writing – review and editing: GCO, VZ, XH, NRF, EJA, AEWH, AJ, MSB, CLL, GEC, TAD, MWR, JKC, KAB, JAC and SJW.
Funding: Funding for this study was provided by Novartis as an Investigator Initiated Trial and by the Mayo Clinic Cancer Center (NCI CA15083).
Competing interests: GC-O and SJW report grants from Novartis during the conduct of the study. MSB reports grants from Immune Design, Pharmacyclics, Marker Therapeutics, Merck, Genentech and Bristol Myers Squibb, outside the submitted work. We certify that the other authors have no financial affiliation/interest (eg, employment, stock holdings, consultant arrangements, honoraria in the subject matter, materials or products) mentioned in this manuscript.
Patient consent for publication: Not required.
Provenance and peer review: Not commissioned; externally peer-reviewed.
Data availability statement: All data relevant to the study are included in the article or uploaded as supplementary information. All relevant data is included in the article.
Author note: Published in abstract form: Colon-Otero G, Weroha SJ, Zanfagnin V, et al. Results of a phase II trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. J Clin Oncol 2019;37 (suppl):abstr 5510. doi: 10.1200/JCO.2019.37.15_suppl.5510.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.